Neurogene (NGNE) announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, president and CFO, to its Board of Directors. Shafer most recently served as Senior Vice President and General Manager, North America, of Avidity Biosciences.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
- 3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
- Neurogene price target lowered to $180 from $200 at Canaccord
- Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
- Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts